Dianthus therapeutics announces two poster presentations for dnth103 at the 10th congress of the european academy of neurology (ean)

New york and waltham, mass., june 28, 2024 (globe newswire) -- dianthus therapeutics, inc. (nasdaq: dnth), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced two poster presentations for dnth103 at the 10th congress of the european academy of neurology (ean), taking place june 29-july 2, 2024 in helsinki.
DNTH Ratings Summary
DNTH Quant Ranking